Protalix BioTherapeutics (PLX) Current Assets (2010 - 2026)
Protalix BioTherapeutics' quarterly Current Assets came in at $86.4 million in Q1 2026, up 42.7% year-on-year from $60.5 million in Q1 2025, and up 29.52% quarter-over-quarter from $66.7 million in Q4 2025.
Protalix BioTherapeutics has reported Current Assets for 17 years, with the latest figure at $86.4 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 42.7% year-over-year to $86.4 million; the trailing twelve-month figure through Mar 2026 stood at $86.4 million (up 42.7% YoY), and the FY2025 full-year result was $66.7 million, up 10.98% from the prior year.
- Current Assets for Q1 2026 stood at $86.4 million, up from $66.7 million in the prior quarter.
- The five-year high for Current Assets was $86.4 million in Q1 2026, with the low at $44.9 million in Q4 2022.
- Average Current Assets over 5 years is $63.2 million, with a median of $65.5 million recorded in 2025.
- Year-over-year, Current Assets tumbled 48.19% in 2022 and surged 58.69% in 2023.
- Tracing PLX's Current Assets over 5 years: stood at $44.9 million in 2022, then jumped by 55.82% to $69.9 million in 2023, then dropped by 14.09% to $60.1 million in 2024, then rose by 10.98% to $66.7 million in 2025, then gained by 29.52% to $86.4 million in 2026.
- The last three Current Assets figures came in at $86.4 million (Q1 2026), $66.7 million (Q4 2025), and $66.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 86.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.36 Mn |
| Dec 31, 2025 | 66.67 Mn |
| Sep 30, 2025 | 66.50 Mn |
| Jun 30, 2025 | 65.49 Mn |
| Mar 31, 2025 | 60.51 Mn |
| Dec 31, 2024 | 60.08 Mn |
| Sep 30, 2024 | 47.85 Mn |
| Jun 30, 2024 | 77.37 Mn |
| Mar 31, 2024 | 75.40 Mn |
| Dec 31, 2023 | 69.93 Mn |
| Sep 30, 2023 | 72.62 Mn |
| Jun 30, 2023 | 73.58 Mn |
| Mar 31, 2023 | 55.40 Mn |
| Dec 31, 2022 | 44.88 Mn |
| Sep 30, 2022 | 45.76 Mn |
| Jun 30, 2022 | 49.70 Mn |
| Mar 31, 2022 | 56.54 Mn |
| Dec 31, 2021 | 61.67 Mn |
| Sep 30, 2021 | 71.22 Mn |
| Jun 30, 2021 | 95.92 Mn |
| Mar 31, 2021 | 90.70 Mn |
| Dec 31, 2020 | 55.72 Mn |
| Sep 30, 2020 | 60.33 Mn |
| Jun 30, 2020 | 54.21 Mn |
| Mar 31, 2020 | 57.77 Mn |
| Dec 31, 2019 | 32.48 Mn |
| Sep 30, 2019 | 40.44 Mn |
| Jun 30, 2019 | 41.60 Mn |
| Mar 31, 2019 | 47.34 Mn |
| Dec 31, 2018 | 52.98 Mn |
| Sep 30, 2018 | 57.34 Mn |
| Jun 30, 2018 | 43.05 Mn |
| Mar 31, 2018 | 55.69 Mn |
| Dec 31, 2017 | 62.65 Mn |
| Sep 30, 2017 | 51.15 Mn |
| Jun 30, 2017 | 48.89 Mn |
| Mar 31, 2017 | 61.54 Mn |
| Dec 31, 2016 | 71.87 Mn |
| Sep 30, 2016 | 59.65 Mn |
| Jun 30, 2016 | 67.65 Mn |
| Mar 31, 2016 | 76.27 Mn |
| Dec 31, 2015 | 85.88 Mn |
| Dec 31, 2014 | 65.52 Mn |
| Mar 31, 2014 | 88.56 Mn |
| Dec 31, 2013 | 97.90 Mn |
| Sep 30, 2013 | 105.20 Mn |
| Jun 30, 2013 | 45.93 Mn |
| Mar 31, 2013 | 52.89 Mn |
| Dec 31, 2012 | 61.17 Mn |
| Sep 30, 2012 | 59.58 Mn |
| Jun 30, 2012 | 65.89 Mn |
| Mar 31, 2012 | 49.84 Mn |
| Dec 31, 2011 | 32.49 Mn |
| Sep 30, 2011 | 40.28 Mn |
| Jun 30, 2011 | 51.20 Mn |
| Dec 31, 2010 | 46.33 Mn |